99mTc-MIBI imaging for prediction of therapeutic effects of second-generation MDR1 inhibitors in malignant brain tumors

International Journal of Cancer

Volumn 121, Issue 12, 2007, Pages 2637-2645

  Sasajima, Toshio ^a   Shimada, Naoya ^a   Naitoh, Yuichiro ^a   Takahashi, Masataka ^a   Hu, Yi ^a   Satoh, Tomo ^a   Mizoi, Kazuo ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

99mTc MIBI; Malignant brain tumors; MS 209; Multidrug resistance; PSC833

Indexed keywords

5 [3 (4 DIPHENYLACETYL 1 PIPERAZINYL) 2 HYDROXYPROPOXY]QUINOLINE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN INHIBITOR; VALSPODAR; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; GLIOMA; IN VITRO STUDY; ISOTOPE LABELING; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTORADIOGRAPHY; BRAIN NEOPLASMS; CARCINOMA 256, WALKER; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOSPORINE; CYCLOSPORINS; CYTOTOXINS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; P-GLYCOPROTEIN; PREDICTIVE VALUE OF TESTS; QUINOLINES; RADIOPHARMACEUTICALS; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TECHNETIUM TC 99M SESTAMIBI; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VINCRISTINE;

EID: 36248929372     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23011     Document Type: Article

References (57)

1. Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM, Pastan I. The human multidrug resistance (mdr1) gene. J Biol Chem 1987; 262:505-8.
2. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987; 84:3004-8.
3. Yamamoto Y, Nishiyama Y, Satoh K, Takashima H, Ohkawa M, Fujita J, Kishi T, Matsuno S, Tanabe M. Comparative study of technetium-99m-sestamibi and thallium-201 SPECT in predicting chemotherapeutic response in small cell lung cancer. J Nucl Med 1998; 39:1626-9.
4. Takamura Y, Miyoshi Y, Taguchi T, Noguchi S. Prediction of chemotherapeutic response by Technetium 99m-MIBI scintigraphy in breast carcinoma patients. Cancer 2001;92:232-9.
5. Cordobes MD, Starzec A, Delmon-Moingeon L, Blanchot C, Kouyoumdjian JC, Prévost G, Caglar M, Moretti JL. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression. J Nucl Med 1996;37: 286-9.
6. Rao VV, Chiu ML, Kronauge JF, Piwnica-Worms D. Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi. J Nucl Med 1994;35:510-5.
7. 99mTc- sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: in vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant. Nucl Med Commun 1995;16:253-7.
8. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993;53:977-84.
9. Tatsumi M, Tsuruo T, Nishimura T. Evaluation of MS-209, a novel multidrug-resistance-reversing agent, in tumour-bearing mice by technetium-99m-MIBI imaging. Eur J Nucl Med 2002;29:288-94.
10. Andrews DW, Das R, Kim S, Zhang J, Curtis M. Technetium-MIBI as a glioma imaging agent for the assessment of multi-drug resistance. Neurosurgery 1997;40:1323-34.
11. Kunishio K, Morisaki K, Matsumoto Y, Nagao S, Nishiyama Y. Technetium-99m sestamibi single photon emission computed tomography findings correlated with P-glycoprotein expression, encoded by the multidrug resistance gene-1 messenger ribonucleic acid, in intracranial meningiomas. Neuro Med Chir (Tokyo) 2003;43:573-81.
12. Nagamachi S, Jinnouchi S, Ohnishi T, Nakahara H, Flores L, II, Tamura S, Yokogami K, Kawano H, Wakisaka S. The usefulness of Tc-99m MIBI for evaluating brain tumors: comparative study with Tl-201 and relation with P-glycoprotein. Clin Nucl Med 1999;24: 765-72.
13. 99mTc-sestamibi brain SPECT after chemoradiotherapy is prognostic of survival in patients with high-grade glioma. J Nucl Med 2004;45:409-13.
14. Le Jeune FP, Dubois F, Blond S, Steinling M. Sestamibi technetium-99m brain single-photon emission computed tomography to identify recurrent glioma in adults: 201 studies. J Neurooncol 2006;77: 177-83.
15. 201Tl. Neuroradiology 2001;43:1023-30.
16. Tomura N, Hirano H, Watanabe O, Kato K, Sasaki K, Watarai J, Sasajima H, Ito Y, Mineura K. Preliminary results with technetium-99m MIBI SPECT imaging in patients with brain tumors: correlation with histological and neuroradiological diagnoses and therapeutic response. Comput Med Imaging Graph 1997;21:293-8.
17. 99mTc-sestamibi SPECT? Eur J Nucl Med 1998;25:401-9.
18. Naito M, Oh-hara T, Yamazaki A, Danki T, Tsuruo T. Reversal of multidrug resistance by an immunosuppressive agent FK-506. Cancer Chemother Pharmacol 1992;29:195-200.
19. Naito M, Tsuge H, Kuroko C, Koyama T, Tomida A, Tatsuta T, Heike Y, Tsuruo T. Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance. J Natl Cancer Inst 1993;85: 311-16.
20. Watanabe T, Tsuge H, Oh-hara T, Naito M, Tsuruo T. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol 1995; 34:235-41.
21. Naito M, Tsuruo T. New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833. Cancer Chemother Pharmacol 1997;40: S20-4.
22. Barbarics E, Kronauge JF, Cohen D, Davison A, Jones AG, Croop JM. Characterization of P-glycoprotein transport and inhibition in vivo. Cancer Res 1998;58:276-82.
23. Kankesan J, Vanama R, Yusuf A, Thiessen JJ, Ling V, Rao PM, Rajalakshmi S, Sarma DS. Effect of PSC 833, an inhibitor of P-glycoprotein on N-methyl-N-nitrosourea induced mammary carcinogenesis in rats. Carcinogenesis 2004;25:425-30.
24. Kusunoki N, Takara K, Tanigawara Y, Yamauchi A, Ueda K, Komada F, Ku Y, Kuroda Y, Saitoh Y, Okumura K. Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein. Jpn J Cancer Res 1998;89:1220-8.
25. 99mTc-sestamibi and doxorubicin to monitor inhibition of P-glycoprotein function. Br J Cancer 2001;84:367-73.
26. Wigler PW. PSC833, cyclosporinA, and dexniguldipine effects on cellular calcein retention and inhibition of the multidrug resistance pump in human leukemic lymphoblasts. Biochem Biophys Res Commun 1999;257:410-13.
27. Baba M, Nakanishi O, Sato W, Saito A, Miyama Y, Yano O, Shimada S, Fukazawa N, Naito M, Tsuruo T. Relationship between multidrug resistant gene expression and multidrug resistant-reversing effect of MS-209 in various tumor cells. Cancer Chemother Pharmacol 1995; 36:361-7.
28. Naito M, Matsuba Y, Sato S, Hirata H, Tsuruo T. MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models. Clin Cancer Res 2002;8:582-8.
29. Nakanishi O, Baba M, Saito A, Yamashita T, Sato W, Abe H, Fukazawa N, Suzuki T, Sato S, Naito M, Tsuruo T. Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines. Oncol Res 1997;9,61-9.
30. Sato W, Fukazawa N, Nakanishi O, Baba M, Suzuki T, Yano O, Naito M, Tsuruo T. Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemother Pharmacol 1995;35:271-7.
31. Saeki T, Nomizu T, Toi M, Ito Y, Noguchi S, Kobayashi T, Asaga T, Minami H, Yamamoto N, Aogi K, Ikeda T, Ohashi Y, et al. Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer. J Clin Oncol 2007;25:411-17.
32. Bates SE, Bakke S, Kang M, Robey RW, Zhai S, Thambi P, Chen CC, Patil S, Smith T, Steinberg SM, Merino M, Goldspiel B, et al. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clin Cancer Res 2004;10:4724-33.
33. Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, Dugan K, Lum B, Chin DL, Dewald G, Paietta E, Bennett JM, et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 2004;22:1078-86.
34. Friedenberg WR, Rue M, Blood EA, Dalton WS, Shustik C, Larson RA, Sonneveld P, Greipp PR. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer 2006;106:830-8.
35. Diéras V, Bonneterre J, Laurence V, Degardin M, Pierga JY, Bonneterre ME, Marreaud S, Lacombe D, Fumoleau P. Phase I combining a P- glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignancies. Clin Cancer Res 2005;11: 6256-60.
36. Sasajima T, Miyagawa T, Oku T, Gelovani JG, Finn R, Blasberg R. Proliferation-dependent changes in amino acid transport and glucose metabolism in glioma cell lines. Eur J Nucl Med Mol Imaging 2004;31:1244-56.
37. 6-methylguanine-DNA methyltransferase mRNA in human brain tumors. Biochim Biophys Acta 1996;1289:105-9.
38. Mineura K, Sasajima T, Sasajima H, Kowada M. Inhibition of methionine uptake by cis-diamminedichloroplatinum (II) in experimental brain tumors. Int J Cancer 1996;67:681-3.
39. Sasajima T, Mineura K, Kowada M, Hatazawa J, Miura S. Intracarotid recombinant human tumor necrosis factor-α reduces cerebral blood flow and methionine uptake in rat brain tumors. J Neurooncol 1997;34:123-9.
40. Birner P, Ritzi M, Musahl C, Knippers R, Gerdes J, Voigtländer T, Budka H, Hainfellner JA. Immunohistochemical detection of cell growth fraction in formalin-fixed and paraffin-embedded murine tissue. Am J Pathol 2001;158:1991-6.
41. Muskhelishvili L, Latendresse JR, Kodell RL, Henderson EB. Evaluation of cell proliferation in rat tissues with BrdU, PCNA, Ki-67 (MIB-5) immunohistochemistry and in situ hybridization for histone mRNA. J Histochem Cytochem 2003;51:1681-8.
42. Hendrikse NH, Franssen EJF, van der Graaf WTA, Vaalburg W, de Vries EGE. Visualization of multidrug resistance in vivo. Eur J Nucl Med 1999;26:283-93.
43. Nakamura T, Oka M, Aizawa K, Soda H, Fukuda M, Terashi K, Ikeda K, Mizuta Y, Noguchi Y, Kimura Y, Tsuruo T, Kohno S. Direct interaction between a quinoline derivative, MS-209, and multidrug resistance protein (MRP) in human gastric cancer cells. Biochem Biophys Res Commun 1999;255:618-24.
44. Narasaki F, Oka M, Fukuda M, Nakano R, Ikeda K, Takatani H, Terashi K, Soda H, Yano O, Nakamura T, Doyle LA, Tsuruo T, et al. A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multidrug resistance-associated protein (MRP) gene. Cancer Chemother Pharmacol 1997;40: 425-32.
45. Utsunomiya K, Ballinger JR, Piquette-Miller M, Rauth AM, Tang W, Su ZF, Ichise M. Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line. Eur J Nucl Med 2000;27: 1786-92.
46. 99mTc-MIBI and comparison with expression of MDR1 mRNA. Akita J Med 2004;31:11-21 (in Japanese).
47. Márián T, Szabó G, Goda K, Nagy H, Szincsák N, Juhász I, Galuska L, Balkay L, Mikecz P, Trón L, Krasznai Z. In vivo and in vitro multitracer analyses of P-glycoprotein expression-related multidrug resistance. Eur J Nucl Med Mol Imaging 2003;30:1147-54.
48. 99mTc-labeled sestamibi and tetrofosmin. Nucl Med Biol 2005;32:573-83.
49. Elsinga PH, Hendrikse NH, Bart J, Vaalburg W, van Waarde A. PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr Pharm Des 2004;10:1493-503.
50. Hendrikse NH, Schinkel AH, de Vries EGE, Fluks E, Van der Graaf WTA, Willemsen ATM, Vaalburg W, Franssen EJF. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol 1998;124:1413-18.
51. Lemaire M, Bruelisauer A, Guntz P, Sato H. Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats. Cancer Chemother Pharmacol 1996;38: 481-6.
52. 11C]verapamil measured with PET. Neuroimage 2003;20:1775-82.
53. 11C-methyl)-L-methionine uptake index in gliomas following radiotherapy. Jpn J Cancer Clin 1989;35:1101-4 (in Japanese).
54. Herholz K, Kracht LW, Heiss WD. Monitoring the effect of chemotherapy in a mixed glioma by C-11-methionine PET. J Neuroimaging 2003;13:269-71.
55. Song S, Suzuki H, Kawai R, Sugiyama Y. Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. Drug Metab Dispos 1999;27:689-94.
56. Drion N, Lemaire M, Lefauconnier JM, Scherrmann JM. Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine. J Neurochem 1996;67:1688-93.
57. Bailly JD, Muller C, Jaffrézou JP, Demur C, Gassar G, Bordier C, Laurent G. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. Leukemia. 1995; 9:799-807.